UROV Urovant Sciences Ltd.

7.64
-0.69  -8%
Previous Close 8.33
Open 8.43
Price To Book 2.27
Market Cap 231667040
Shares 30,322,911
Volume 39,728
Short Ratio
Av. Daily Volume 73,211

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a trial to be initiated in 2019.
hMaxi-K
Overactive bladder (OAB)
Phase 2a initiation of enrolment announced January 3, 2019.
Vibegron
Irritable bowel syndrome (IBS)
Phase 3 trial initiation announced March 27, 2019.
Vibegron - COURAGE
Overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH)
Phase 3 data released March 18, 2019 - primary endpoints met.
Vibegron
Overactive bladder (OAB)

Latest News

  1. Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting
  2. Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting
  3. Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
  4. Here's Why Urovant Sciences Got Whacked on "Positive" Clinical Trial Data
  5. Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
  6. Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
  7. Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
  8. Urovant Sciences Appoints James Robinson to its Board of Directors
  9. Codexis Inc (CDXS) Q4 2018 Earnings Conference Call Transcript
  10. Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
  11. Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018
  12. Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results
  13. Urovant Sciences to Host R&D Day for Investors and Analysts on February 7, 2019
  14. Urovant Sciences Initiates Patient Enrollment in Phase 2a Clinical Trial for Vibegron in Patients with Abdominal Pain Due to Irritable Bowel Syndrome
  15. Roivant Sciences to Present at the 37th Annual J.P. Morgan Healthcare Conference
  16. Urovant Sciences to Present at the J.P. Morgan 37th Annual Healthcare Conference
  17. Urovant Sciences Announces Participation in Piper Jaffray Healthcare Conference
  18. Urovant Sciences Reports Financial Results for the Second Fiscal Quarter Ended September 30, 2018 and Provides Corporate Update
  19. Urovant Sciences Completes Patient Enrollment in Phase 3 Pivotal Trial Studying Vibegron for Overactive Bladder
  20. Urovant Sciences to Report 2018 Second Fiscal Quarter Financial Results